Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Esophageal Neoplasms × Watchful Waiting × Clear all

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 10 Neoplasms 9 Breast Neoplasms 8 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lung Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Thrombocythemia, Essential 2 Testicular Neoplasms 2 Stomach Neoplasms 2 Skin Diseases 2 Primary Myelofibrosis 2 Polycythemia Vera 2 Myeloproliferative Disorders 2 Melanoma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia 2 Hodgkin Disease 2 Hematologic Diseases 2 Burkitt Lymphoma 2 Breast Neoplasms, Male 2 Waldenstrom Macroglobulinemia 1 Vulvar Neoplasms 1 Uveal Melanoma 1 Urinary Bladder Neoplasms 1

Interventions

Esophagectomy 13 Blood Specimen Collection 10 Surgical Procedures, Operative 8 Radiotherapy 8 Surveys and Questionnaires 5 Endoscopic Mucosal Resection 5 Specimen Handling 4 Neoadjuvant Therapy 4 Drug Therapy 4 Biopsy 4 Tissue Banks 3 Psychiatric Rehabilitation 3 Positron Emission Tomography Computed Tomography 3 Observation 3 Magnetic Resonance Spectroscopy 3 Immunohistochemistry 3 Endoscopy 3 Diffusion Magnetic Resonance Imaging 3 Breath Tests 3 anlotinib 2 Polymerase Chain Reaction 2 Platinum Compounds 2 Paclitaxel 2 Immunotherapy 2 Gastroscopy 2 Fiducial Markers 2 Endoscopic Ultrasound-Guided Fine Needle Aspiration 2 Dynamic Contrast Enhanced Magnetic Resonance Imaging 2 Amplified Fragment Length Polymorphism Analysis 2 trastuzumab deruxtecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04886635 2024-02-20

SANO-2

Erasmus Medical Center

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡